kynurenic acid has been researched along with Psychoses in 17 studies
Kynurenic Acid: A broad-spectrum excitatory amino acid antagonist used as a research tool.
kynurenic acid : A quinolinemonocarboxylic acid that is quinoline-2-carboxylic acid substituted by a hydroxy group at C-4.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Evidence, largely obtained from peripheral studies, suggests that alterations in the kynurenine pathway contribute to the aetiology of depression and disorders involving psychosis." | 8.12 | Alterations in the kynurenine pathway and excitatory amino acid transporter-2 in depression with and without psychosis: Evidence of a potential astrocyte pathology. ( Brown, AM; Brown, SJ; Huang, XF; Newell, KA; Purves-Tyson, TD; Shannon Weickert, C, 2022) |
| "Abnormalities in the kynurenine pathway (KP) of tryptophan degradation, leading to the dysfunction of neuroactive KP metabolites in the brain, have been implicated in the pathophysiology of schizophrenia (SZ)." | 7.88 | Influence of plasma cytokines on kynurenine and kynurenic acid in schizophrenia. ( Chiappelli, J; Hong, LE; Notarangelo, FM; Pocivavsek, A; Rowland, LM; Schwarcz, R; Thomas, MAR, 2018) |
| " Levels of kynurenic acid (KYNA) in saliva increase in response to psychological stress, and this stress-induced effect may be abnormal in people with schizophrenia." | 7.88 | Salivary kynurenic acid response to psychological stress: inverse relationship to cortical glutamate in schizophrenia. ( Chiappelli, J; Hong, LE; Jones, A; Kochunov, P; Notarangelo, FM; Pocivavsek, A; Rowland, LM; Schwarcz, R; Thomas, MAR; Wijtenburg, SA; Wisner, K, 2018) |
| "Elevated cerebrospinal fluid (CSF) levels of the glia-derived N-methyl-D-aspartic acid receptor antagonist kynurenic acid (KYNA) have consistently been implicated in schizophrenia and bipolar disorder." | 7.83 | A genome-wide association study of kynurenic acid in cerebrospinal fluid: implications for psychosis and cognitive impairment in bipolar disorder. ( Backlund, L; Bergen, SE; Ekman, CJ; Engberg, G; Erhardt, S; Hultman, CM; Kegel, ME; Landén, M; Larsson, M; Lichtenstein, P; Magnusson, PK; Olsson, S; Schalling, M; Sellgren, CM; Sklar, P; Smoller, JW; Sullivan, PF; Svensson, CI; Vawter, MP; Walther-Jallow, L, 2016) |
| "Schizophrenia is a chronic psychotic disease burdened by cognitive deficits which hamper daily functioning causing disability and costs for society." | 7.01 | Importance of the dysregulation of the kynurenine pathway on cognition in schizophrenia: a systematic review of clinical studies. ( Bosia, M; Comai, S; Guillemin, GJ; Sapienza, J; Spangaro, M, 2023) |
| "Evidence, largely obtained from peripheral studies, suggests that alterations in the kynurenine pathway contribute to the aetiology of depression and disorders involving psychosis." | 4.12 | Alterations in the kynurenine pathway and excitatory amino acid transporter-2 in depression with and without psychosis: Evidence of a potential astrocyte pathology. ( Brown, AM; Brown, SJ; Huang, XF; Newell, KA; Purves-Tyson, TD; Shannon Weickert, C, 2022) |
| "Risks of autoimmune processes causing schizophrenia are associated with several factors: an impaired functioning of dopaminergic and glutamatergic systems in the brain, kynurenine pathway disorder with overproduction of quinolinic, anthranilic, and kynurenic acids (possibly altering both neurons and T-regulators), increased intestinal permeability, as well as food antigens' effects, stress and infections with various pathogens at different stages of ontogenesis." | 4.02 | Autoimmune Concept of Schizophrenia: Historical Roots and Current Facets. ( Butoma, BG; Churilov, LP; Gilburd, B; Mayorova, MA; Petrova, NN; Shoenfeld, Y, 2021) |
| "Abnormalities in the kynurenine pathway (KP) of tryptophan degradation, leading to the dysfunction of neuroactive KP metabolites in the brain, have been implicated in the pathophysiology of schizophrenia (SZ)." | 3.88 | Influence of plasma cytokines on kynurenine and kynurenic acid in schizophrenia. ( Chiappelli, J; Hong, LE; Notarangelo, FM; Pocivavsek, A; Rowland, LM; Schwarcz, R; Thomas, MAR, 2018) |
| " Levels of kynurenic acid (KYNA) in saliva increase in response to psychological stress, and this stress-induced effect may be abnormal in people with schizophrenia." | 3.88 | Salivary kynurenic acid response to psychological stress: inverse relationship to cortical glutamate in schizophrenia. ( Chiappelli, J; Hong, LE; Jones, A; Kochunov, P; Notarangelo, FM; Pocivavsek, A; Rowland, LM; Schwarcz, R; Thomas, MAR; Wijtenburg, SA; Wisner, K, 2018) |
| " Depression is hypothesized to be causally associated with an imbalance in the kynurenine pathway, with an increased metabolism down the 3-hydroxykynurenine (3HK) branch of the pathway leading to increased levels of the neurotoxic metabolite, quinolinic acid (QA), which is a putative N-methyl-d-aspartate (NMDA) receptor agonist." | 3.85 | Serum kynurenic acid is reduced in affective psychosis. ( Bliss, SA; Dantzer, R; Drevets, WC; Ford, BN; McMillin, JR; Morris, HM; Savitz, JB; Suzuki, H; Teague, TK; Wurfel, BE, 2017) |
| "Increased cytokines and kynurenic acid (KYNA) levels in cerebrospinal fluid (CSF) have been reported in patients with schizophrenia and bipolar disorder." | 3.85 | Kynurenic acid and psychotic symptoms and personality traits in twins with psychiatric morbidity. ( Bhat, M; Cannon, TD; Engberg, G; Erhardt, S; Hultman, CM; Johansson, V; Kegel, ME; Landén, M; Schuppe-Koistinen, I; Schwieler, L; Wetterberg, L, 2017) |
| "Elevated cerebrospinal fluid (CSF) levels of the glia-derived N-methyl-D-aspartic acid receptor antagonist kynurenic acid (KYNA) have consistently been implicated in schizophrenia and bipolar disorder." | 3.83 | A genome-wide association study of kynurenic acid in cerebrospinal fluid: implications for psychosis and cognitive impairment in bipolar disorder. ( Backlund, L; Bergen, SE; Ekman, CJ; Engberg, G; Erhardt, S; Hultman, CM; Kegel, ME; Landén, M; Larsson, M; Lichtenstein, P; Magnusson, PK; Olsson, S; Schalling, M; Sellgren, CM; Sklar, P; Smoller, JW; Sullivan, PF; Svensson, CI; Vawter, MP; Walther-Jallow, L, 2016) |
| "The kynurenine pathway metabolite kynurenic acid (KYNA), modulating glutamatergic and cholinergic neurotransmission, is increased in cerebrospinal fluid (CSF) of patients with schizophrenia or bipolar disorder type 1 with psychotic features." | 3.80 | The KMO allele encoding Arg452 is associated with psychotic features in bipolar disorder type 1, and with increased CSF KYNA level and reduced KMO expression. ( Backlund, L; Cichon, S; Engberg, G; Erhardt, S; Frisén, L; Landén, M; Lavebratt, C; Nikamo, P; Olsson, S; Osby, U; Priebe, L; Schalling, M; Sellgren, C; Träskman-Bendz, L; Vawter, MP, 2014) |
| "Schizophrenia is a chronic psychotic disease burdened by cognitive deficits which hamper daily functioning causing disability and costs for society." | 3.01 | Importance of the dysregulation of the kynurenine pathway on cognition in schizophrenia: a systematic review of clinical studies. ( Bosia, M; Comai, S; Guillemin, GJ; Sapienza, J; Spangaro, M, 2023) |
| "Kynurenic acid (KYNA) is a KP metabolite synthesized by kynurenine aminotransferases (KATs) from its biological precursor kynurenine and acts as an endogenous antagonist of N-methyl-D-aspartate and α7-nicotinic acetylcholine receptors." | 1.62 | Prenatal Kynurenine Elevation Elicits Sex-Dependent Changes in Sleep and Arousal During Adulthood: Implications for Psychotic Disorders. ( Baratta, AM; Ditty, AL; Milosavljevic, S; Mong, JA; Pocivavsek, A; Rentschler, KM; Wagner, NTJ; Wright, CJ, 2021) |
| "Kynurenine was significantly lower in patients with PP and PD as compared to healthy postpartum women (p=0." | 1.43 | Tryptophan pathway alterations in the postpartum period and in acute postpartum psychosis and depression. ( Bergink, V; Burgerhout, KM; Drexhage, HA; Hoogendijk, WJ; Kushner, SA; Myint, AM; Schütze, G; Schwarz, MJ; Veen, C, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (5.88) | 29.6817 |
| 2010's | 11 (64.71) | 24.3611 |
| 2020's | 5 (29.41) | 2.80 |
| Authors | Studies |
|---|---|
| Brown, SJ | 1 |
| Brown, AM | 1 |
| Purves-Tyson, TD | 1 |
| Huang, XF | 1 |
| Shannon Weickert, C | 1 |
| Newell, KA | 1 |
| Sapienza, J | 3 |
| Spangaro, M | 3 |
| Guillemin, GJ | 3 |
| Comai, S | 3 |
| Bosia, M | 3 |
| Rentschler, KM | 1 |
| Baratta, AM | 1 |
| Ditty, AL | 1 |
| Wagner, NTJ | 1 |
| Wright, CJ | 1 |
| Milosavljevic, S | 1 |
| Mong, JA | 1 |
| Pocivavsek, A | 3 |
| Mayorova, MA | 1 |
| Butoma, BG | 1 |
| Churilov, LP | 1 |
| Gilburd, B | 1 |
| Petrova, NN | 1 |
| Shoenfeld, Y | 1 |
| Sellgren, CM | 3 |
| Imbeault, S | 1 |
| Larsson, MK | 1 |
| Oliveros, A | 1 |
| Nilsson, IAK | 1 |
| Codeluppi, S | 1 |
| Orhan, F | 1 |
| Bhat, M | 2 |
| Tufvesson-Alm, M | 1 |
| Gracias, J | 2 |
| Kegel, ME | 3 |
| Zheng, Y | 1 |
| Faka, A | 1 |
| Svedberg, M | 1 |
| Powell, SB | 1 |
| Caldwell, S | 1 |
| Kamenski, ME | 1 |
| Vawter, MP | 3 |
| Schulmann, A | 1 |
| Goiny, M | 1 |
| Svensson, CI | 2 |
| Hökfelt, T | 1 |
| Schalling, M | 3 |
| Schwieler, L | 4 |
| Cervenka, S | 1 |
| Choi, DS | 1 |
| Landén, M | 6 |
| Engberg, G | 6 |
| Erhardt, S | 7 |
| Wurfel, BE | 1 |
| Drevets, WC | 1 |
| Bliss, SA | 1 |
| McMillin, JR | 1 |
| Suzuki, H | 1 |
| Ford, BN | 1 |
| Morris, HM | 1 |
| Teague, TK | 1 |
| Dantzer, R | 1 |
| Savitz, JB | 1 |
| Chiappelli, J | 2 |
| Notarangelo, FM | 2 |
| Thomas, MAR | 2 |
| Rowland, LM | 2 |
| Schwarcz, R | 2 |
| Hong, LE | 2 |
| Wijtenburg, SA | 1 |
| Jones, A | 1 |
| Wisner, K | 1 |
| Kochunov, P | 1 |
| Jungholm, O | 1 |
| Perlis, RH | 1 |
| Curto, M | 1 |
| Lionetto, L | 1 |
| Fazio, F | 1 |
| Corigliano, V | 1 |
| Comparelli, A | 1 |
| Ferracuti, S | 1 |
| Simmaco, M | 1 |
| Nicoletti, F | 1 |
| Baldessarini, RJ | 1 |
| Lavebratt, C | 1 |
| Olsson, S | 2 |
| Backlund, L | 2 |
| Frisén, L | 1 |
| Sellgren, C | 2 |
| Priebe, L | 1 |
| Nikamo, P | 1 |
| Träskman-Bendz, L | 1 |
| Cichon, S | 1 |
| Osby, U | 1 |
| Veen, C | 1 |
| Myint, AM | 1 |
| Burgerhout, KM | 1 |
| Schwarz, MJ | 1 |
| Schütze, G | 1 |
| Kushner, SA | 1 |
| Hoogendijk, WJ | 1 |
| Drexhage, HA | 1 |
| Bergink, V | 1 |
| Bergen, SE | 1 |
| Ekman, CJ | 1 |
| Larsson, M | 1 |
| Sullivan, PF | 1 |
| Sklar, P | 1 |
| Smoller, JW | 1 |
| Magnusson, PK | 1 |
| Hultman, CM | 2 |
| Walther-Jallow, L | 1 |
| Lichtenstein, P | 1 |
| Johansson, V | 1 |
| Wetterberg, L | 1 |
| Cannon, TD | 1 |
| Schuppe-Koistinen, I | 1 |
| Carlborg, A | 1 |
| Jokinen, J | 1 |
| Jönsson, EG | 1 |
| Nordström, P | 1 |
| Olsson, SK | 1 |
| Atlas, A | 1 |
| Gisslén, M | 1 |
| Nordin, C | 1 |
| Lindström, L | 1 |
1 review available for kynurenic acid and Psychoses
| Article | Year |
|---|---|
Importance of the dysregulation of the kynurenine pathway on cognition in schizophrenia: a systematic review of clinical studies.
Topics: Cognition; Humans; Kynurenic Acid; Kynurenine; Psychotic Disorders; Quality of Life; Schizophrenia | 2023 |
Importance of the dysregulation of the kynurenine pathway on cognition in schizophrenia: a systematic review of clinical studies.
Topics: Cognition; Humans; Kynurenic Acid; Kynurenine; Psychotic Disorders; Quality of Life; Schizophrenia | 2023 |
Importance of the dysregulation of the kynurenine pathway on cognition in schizophrenia: a systematic review of clinical studies.
Topics: Cognition; Humans; Kynurenic Acid; Kynurenine; Psychotic Disorders; Quality of Life; Schizophrenia | 2023 |
Importance of the dysregulation of the kynurenine pathway on cognition in schizophrenia: a systematic review of clinical studies.
Topics: Cognition; Humans; Kynurenic Acid; Kynurenine; Psychotic Disorders; Quality of Life; Schizophrenia | 2023 |
16 other studies available for kynurenic acid and Psychoses
| Article | Year |
|---|---|
Alterations in the kynurenine pathway and excitatory amino acid transporter-2 in depression with and without psychosis: Evidence of a potential astrocyte pathology.
Topics: Astrocytes; Depression; Depressive Disorder, Major; Humans; Kynurenic Acid; Kynurenine; Psychotic Di | 2022 |
Prenatal Kynurenine Elevation Elicits Sex-Dependent Changes in Sleep and Arousal During Adulthood: Implications for Psychotic Disorders.
Topics: Animals; Disease Models, Animal; Electroencephalography; Electromyography; Female; Kynurenic Acid; M | 2021 |
Autoimmune Concept of Schizophrenia: Historical Roots and Current Facets.
Topics: Antipsychotic Agents; Humans; Kynurenic Acid; Kynurenine; Psychotic Disorders; Schizophrenia | 2021 |
GRK3 deficiency elicits brain immune activation and psychosis.
Topics: Animals; Bipolar Disorder; Brain; Kynurenic Acid; Mice; Psychotic Disorders; Schizophrenia | 2021 |
Serum kynurenic acid is reduced in affective psychosis.
Topics: Adult; Affective Disorders, Psychotic; Bipolar Disorder; Corpus Striatum; Cytokines; Depression; Dep | 2017 |
Influence of plasma cytokines on kynurenine and kynurenic acid in schizophrenia.
Topics: Adolescent; Adult; Cytokines; Female; Humans; Kynurenic Acid; Kynurenine; Male; Middle Aged; Psychot | 2018 |
Salivary kynurenic acid response to psychological stress: inverse relationship to cortical glutamate in schizophrenia.
Topics: Adult; Female; Glutamic Acid; Gyrus Cinguli; Humans; Kynurenic Acid; Male; Proton Magnetic Resonance | 2018 |
Peripheral and central levels of kynurenic acid in bipolar disorder subjects and healthy controls.
Topics: Adult; Bipolar Disorder; Chromatography, High Pressure Liquid; Depression; Female; Humans; Kynurenic | 2019 |
Serum xanthurenic acid levels: Reduced in subjects at ultra high risk for psychosis.
Topics: Adolescent; Adult; Disease Progression; Female; Humans; Hydroxyindoleacetic Acid; Kynurenic Acid; Ky | 2019 |
The KMO allele encoding Arg452 is associated with psychotic features in bipolar disorder type 1, and with increased CSF KYNA level and reduced KMO expression.
Topics: Adult; Aged; Alleles; Bipolar Disorder; Case-Control Studies; Cell Line; Female; Gene Expression; Ge | 2014 |
Tryptophan pathway alterations in the postpartum period and in acute postpartum psychosis and depression.
Topics: Adult; Depression, Postpartum; Female; Humans; Hydroxyindoleacetic Acid; Kynurenic Acid; Kynurenine; | 2016 |
A genome-wide association study of kynurenic acid in cerebrospinal fluid: implications for psychosis and cognitive impairment in bipolar disorder.
Topics: Adult; Aged; Bipolar Disorder; Brain; Chromosomes, Human, Pair 1; Cognition Disorders; Cognitive Dys | 2016 |
Kynurenic acid and psychotic symptoms and personality traits in twins with psychiatric morbidity.
Topics: Bipolar Disorder; Female; Humans; Interleukin-6; Interleukin-8; Kynurenic Acid; Male; Middle Aged; P | 2017 |
CSF kynurenic acid and suicide risk in schizophrenia spectrum psychosis.
Topics: Adolescent; Adult; Cohort Studies; Female; Follow-Up Studies; Humans; Kynurenic Acid; Linear Models; | 2013 |
Cerebrospinal fluid kynurenic acid is associated with manic and psychotic features in patients with bipolar I disorder.
Topics: Adult; Antimanic Agents; Bipolar Disorder; Chromatography, High Pressure Liquid; Female; Humans; Kyn | 2012 |
Acute psychotic symptoms in HIV-1 infected patients are associated with increased levels of kynurenic acid in cerebrospinal fluid.
Topics: Adult; CD4 Lymphocyte Count; Female; HIV Infections; HIV-1; Humans; Kynurenic Acid; Male; Middle Age | 2007 |